Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.

Nakamura, K; Yamaguchi, T; Ishihara, T; Sudo, K; Kato, H; Saisho, H

Nakamura, K; Yamaguchi, T; Ishihara, T; Sudo, K; Kato, H; Saisho, H.

Affiliation

Nakamura K; Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.

Br J Cancer ; 94(11): 1575-9, 2006 Jun 05.

Article in En | MEDLINE | ID: mdl-16721372

Subject(s)

Deoxycytidine/analogs & derivatives; Oxonic Acid/toxicity; Oxonic Acid/therapeutic use; Pancreatic Neoplasms/drug therapy; Tegafur/toxicity; Tegafur/therapeutic use; Aged; Deoxycytidine/therapeutic use; Deoxycytidine/toxicity; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms/mortality; Pancreatic Neoplasms/pathology; Survival Analysis; Time Factors; Gemcitabine

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxonic Acid / Pancreatic Neoplasms / Tegafur / Deoxycytidine Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2006 Document type: Article

Fulltext

XML

PubMed Links

Search on Google